Sign In
Buy TRCK
$0.643
-0.0072 (-1.11%)
At Close: Jul 31, 2026
Track Group Reports 3rd Quarter Fiscal 2024 Financial Results
10:00am, Friday, 09'th Aug 2024
NAPERVILLE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Track Group, Inc. (OTCQB: TRCK), a global leader in offender tracking and monitoring services, today announced financial results for its fiscal quar
Starz & BritBox Launching New Bundle, Lionsgate On Track To Split By Year End, CEO Says
07:56pm, Thursday, 08'th Aug 2024
Starz and BBC Studios' BritBox will come together on a new bundle next quarter as streamers big and small continue to pair up, said Lionsgate CEO Jon Feltheimer. Starz' strong core demos “make it a
Rivian Stock Drops, but the Electric Vehicle (EV) Maker Remains on Track to Achieve a Gross Profit in Q4
07:32am, Wednesday, 07'th Aug 2024
First-quarter revenue edged up 3% year over year, which was good enough to beat Wall Street's consensus estimate of 1% growth. Adjusted loss was $1.13 per share, narrower than the loss of $1.21 per sh
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
01:33pm, Sunday, 04'th Aug 2024
The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.
Gildan Is Back On Track And Has Good Plans, The Stock Is Fairly Valued
05:01pm, Friday, 02'nd Aug 2024
Gildan Activewear Inc.'s Q2 2024 results were positive, with expected growth and increased market share. The company has levers to solidify its leading market position in the industry. Hold rating on
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, a
This Semiconductor Stock Is ON Track for a New High
10:31am, Tuesday, 30'th Jul 2024
Onsemi's NASDAQ: ON Q2 results were no blowout. Still, its operational quality and outlook for success have the stock price in rebound mode, and the market is on track to hit a one-year high soon.
After A Two-Year Slump, Shoe Carnival Is Back On Track For Growth
06:26am, Saturday, 27'th Jul 2024
Shoe Carnival, Inc. is turning around its fortunes with Q1 of fiscal 2024 being a pivotal point. The company is launching initiatives to grow the business and constrain costs, and they are expected to
Amid Q2 Earnings, Verizon Stock Needs to Do This 1 Thing to Get Back on Track
05:05am, Saturday, 27'th Jul 2024
Verizon holds $149 billion in total debt. A low P/E ratio has offered investors little relief.
Enel Is On Track To Meet Top Range Outlook
03:05am, Saturday, 27'th Jul 2024
The company's solid operating growth, cost-saving initiatives, and disposal program support a positive outlook for shareholders. A positive rating credit update and a better FCF generation in H2 will
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
08:00am, Thursday, 25'th Jul 2024
Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need
PG&E Corporation Reports Second-Quarter Results; On Track to Deliver Solid 2024
06:15am, Thursday, 25'th Jul 2024
OAKLAND, Calif. , July 25, 2024 /PRNewswire/ -- PG&E Corporation (NYSE: PCG) is on track to deliver solid 2024 results.
Texas Instruments on Track for Growth, Recovery in Key Markets And More: Analyst
02:23pm, Wednesday, 24'th Jul 2024
JP Morgan analyst Harlan Sur reiterated an Overweight rating on Texas Instruments Inc TXN with a price target of $230, up from $195.
Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumab
09:40am, Wednesday, 24'th Jul 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares moved higher after the biotechnology firm revealed the US Food and Drug Administration (FDA) has granted Fast Track designation to its intranasal formula
Tiziana Life Sciences Granted FDA Fast Track Designation
07:00am, Wednesday, 24'th Jul 2024
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
